Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Global Infectious Mononucleosis Market - Industry Trends and Forecast to 2028

Pharmaceutical | Upcoming Report | May 2021 | Global | 350 Pages | No of Tables: 220 | No of Figures: 60

Report Description

Global Infectious Mononucleosis Market, By Diagnosis (Physical Examination, Blood Test, Others), Treatment (Medication, Home Remedies, Others), Complications (Neurologic Complications, Hematologic Complications, Splenic Rupture, Respiratory Complications, Hepatic Complications, Others), Stages of Infection (EBV Naive, Acute Primary Infection, Subacute Infection, Convalescent Infection, Past Infection, Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights : Global Infectious Mononucleosis Market

Global Infectious Mononucleosis market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR 6.10% in the above-mentioned research forecast period. Emerging markets and huge investments in research and development are the factors responsible for this market's growth.

The rise in the adolescent population across the world is the vital factor escalating the market growth. Also technological advancements leading to faster diagnosis and rising incidence of infectious mononucleosis (IM) are the major factors among others driving the mononucleosis diagnostic market. Rising R&D investments in the biotechnology sector and modernization will further create new opportunities for the market. However, limitations of available tests for mononucleosis and lack of awareness also create a challenge for the market.

Infectious Mononucleosis is a contagious infection typically caused by the Epstein-Barr virus (EBV). It is also called glandular fever, mono and kissing disease. Infectious Mononucleosis is a clinical entity identified by fatigue, fever, pharyngitis and cervical lymph node enlargement. The virus spread by intimate oral contact among adolescents, although preadolescents spread is unknown till now. The incubation period of the virus is six weeks; during this period viral replication first occurs in the oropharynx followed by viremia as early as two weeks before the onset of illness.

It is estimated that the virus does not produce any symptoms in children, but only 10% of children who become infected with EBV develop the illness. In the U.S., up to 95% of adults 35-40 years of age have antibodies directed against EBV. The most common signs and symptoms are fatigue (70%), sore throat (95%), upper respiratory symptoms (65%), cervical lymphadenopathy (80%), headache (50%) and others.

This Infectious Mononucleosis market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Infectious Mononucleosis Market Scope and Market Size

The Infectious Mononucleosis market is segmented on the basis of diagnosis, treatment, complications, stages of infection, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of diagnosis, the Infectious Mononucleosis market is segmented into physical examination, blood test and others. Blood test further segmented into antibody tests, white blood cell count and others.
  • On the basis of treatment, the Infectious Mononucleosis market is segmented into medication, home remedies and others. Medication segment further segmented into corticosteroids, analgesics and others. Home remedies further divided into warm water, salt water gargles, fruit juice and others.
  • On the basis of complication, the Infectious Mononucleosis market is segmented into neurologic complications, hematologic complications, splenic rupture, respiratory complications, hepatic complications and others.
  • On the basis of stages of infection, the Infectious Mononucleosis market is segmented into EBV naive, acute primary infection, subacute infection, convalescent infection, past infection and others.
  • On the basis of end-users, the Infectious Mononucleosis market is segmented into hospitals, specialty clinics and others.
  • On the basis of distribution channel, the Infectious Mononucleosis market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.

Infectious Mononucleosis Market Country Level Analysis

Infectious Mononucleosis market is analysed and market size information is provided by country, diagnosis, treatment, complications, stages of infection, end-users and distribution channel as referenced above.

The countries covered in the Infectious Mononucleosis market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts for the largest market share due to the rising incidence of Infectious Mononucleosis and rising research and development. Europe accounts for the second-largest market share due to the presence of refined medical facilities and a high diagnosis rate for Infectious Mononucleosis. Asia-Pacific is expected to account for the largest market share over the coming years for the Infectious Mononucleosis market due to increased advancement in technology as well as growing healthcare expenditure and rising awareness programs.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Infectious Mononucleosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Infectious Mononucleosis Market Share Analysis

Infectious Mononucleosis market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Infectious Mononucleosis market.

The major players covered in the Infectious Mononucleosis market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., LUPIN, Hikma Pharmaceuticals PLC, Sandoz AG, Zydus Cadila, Aurbindo, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, GlaxoSmithKline Plc, Bio-Rad Laboratories, Johnson & Johnson Services, BD, Beckman Coulter, Inc., and bioMérieux SA among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.


SKU-

Table of Content

Please fill in the below form for detailed Table of Content

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Table

Please fill in the below form for detailed List of Table

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Figure

Please fill in the below form for detailed List of Figure

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

View Infographics

Please fill in the below form for detailed Infographics

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country
CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19